Parkinson's DiseasePhase 1NCT02095171
Single Ascending Dose Study of PRX002 in Healthy Subjects
A Phase 1 study testing PRX002 in people with Parkinson's Disease, run by Prothena Biosciences Limited at 1 site in United States.
Trial summary
This single ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX002 in approximately 40 healthy subjects. Read more about this study
- Who is it for?
- Ages 21 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Parkinson's Disease
- What is being tested?
- PRX002
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 40 participants
- Where
- 1 siteUnited States
- Study dates
- Mar 2014to Dec 2014
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Healthy subjects
- Body mass index (BMI) between 18-32 kg/m2 with a minimum weight of 46 kg
- Female subjects must be surgically sterile or post-menopausal or if of child-bearing potential must use contraception
- Male subjects and their partners of childbearing potential must use contraception
Who cannot join
- Positive test for drug of abuse
- Past or current history of alcohol abuse
- Positive for hepatitis B, hepatitis C or HIV infection
Trial locations and contacts
1 site in 1 country.
About this study
Official title: A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX002 Administered by Intravenous Infusion in Healthy Subjects
This single ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX002 in approximately 40 healthy subjects.
- Conditions
- Parkinson's Disease
- Being tested
- PRX002, Placebo
- Medical subject headings
- Parkinson Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PRX002Drug
PlaceboOther
| Study group | Role | What they receive |
|---|---|---|
| PRX002 | Experimental | Not described Receives: Drug: PRX002 |
| Placebo | Placebo comparator | Not described Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety and tolerability as determined by number of subjects with adverse events
Measured: up to 3 months
Determination of pharmacokinetics parameters
- maximum concentration (Cmax)
Measured: up to 3 months
Determination of pharmacokinetics parameters
- time of the maximum measured concentration (Tmax)
Measured: up to 3 months
Determination of pharmacokinetics parameters
- area under the concentration-time curve from time zero to the last quantifiable concentration time-point (AUClast)
Measured: up to 3 months
Determination of pharmacokinetics parameters
- area under the concentration-time curve from time zero extrapolated to infinity (AUCinf)
Measured: up to 3 months
Determination of pharmacokinetics parameters
- elimination rate constant
Measured: up to 3 months
Determination of pharmacokinetics parameters
- terminal elimination half life (t½)
Measured: up to 3 months
Determination of pharmacokinetics parameters
- clearance (CL)
Measured: up to 3 months
Determination of pharmacokinetics parameters
- apparent volume of distribution (Vd)
Measured: up to 3 months
Secondary outcomes (1)
Immunogenicity as determined by measurement of anti-PRX002 antibodies
Measured: up to 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Mar 2014 (estimated)
- Study startMar 2014
- Primary completionDec 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson's DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Prothena Biosciences Limited
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Hoffmann-La Roche
- Responsible party
- Sponsor
- Investigators
- Theresa Neumann, PhD, Study director, Clinical Trials Prothena Biosciences Inc
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02095171
- Sponsor's protocol ID
- PRX002-CL001
- Status last verified
- Feb 2015
- First submitted
- 14 Mar 2014
- Last updated
- 10 Feb 2015
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Feb 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of PRX002 Administered by Intravenous Infusion in Healthy Subjects
- ClinicalTrials.gov ID
- NCT02095171
- Acronym / sponsor ID
- PRX002-CL001
- Conditions
- Parkinson's Disease
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- Prothena Biosciences LimitedIndustry (pharma, biotech, devices)
- Collaborators
- Hoffmann-La Roche
- Study start
- Mar 2014
- Primary completion
- Dec 2014 (actual)
- First posted
- 24 Mar 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This single ascending dose study is to determine safety, tolerability, pharmacokinetics and immunogenicity of PRX002 in approximately 40 healthy subjects.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| PRX002 | Experimental | Drug: PRX002 |
| Placebo | Placebo comparator | Other: Placebo |
Who may qualify
- Ages
- 21 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Healthy subjects
- Body mass index (BMI) between 18-32 kg/m2 with a minimum weight of 46 kg
- Female subjects must be surgically sterile or post-menopausal or if of child-bearing potential must use contraception
- Male subjects and their partners of childbearing potential must use contraception
Key exclusion criteria (3 listed)
- Positive test for drug of abuse
- Past or current history of alcohol abuse
- Positive for hepatitis B, hepatitis C or HIV infection
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PRX002 | Drug | PRX002 |
| Placebo | Other | Placebo |
Primary outcome
Safety and tolerability as determined by number of subjects with adverse events
Time frame: up to 3 months
Determination of pharmacokinetics parameters
Time frame: up to 3 months
- maximum concentration (Cmax)
Determination of pharmacokinetics parameters
Time frame: up to 3 months
- time of the maximum measured concentration (Tmax)
Determination of pharmacokinetics parameters
Time frame: up to 3 months
- area under the concentration-time curve from time zero to the last quantifiable concentration time-point (AUClast)
Determination of pharmacokinetics parameters
Time frame: up to 3 months
- area under the concentration-time curve from time zero extrapolated to infinity (AUCinf)
Determination of pharmacokinetics parameters
Time frame: up to 3 months
- elimination rate constant
Determination of pharmacokinetics parameters
Time frame: up to 3 months
- terminal elimination half life (t½)
Determination of pharmacokinetics parameters
Time frame: up to 3 months
- clearance (CL)
Determination of pharmacokinetics parameters
Time frame: up to 3 months
- apparent volume of distribution (Vd)
1 secondary outcome
Immunogenicity as determined by measurement of anti-PRX002 antibodies
Time frame: up to 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Feb 2015.
Related trials for Parkinson's Disease
Active, not recruitingPhase 3
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
Carcinoma, Renal Cell
Not yet recruiting
The Effects of Ischemic Conditioning in Individuals With Parkinson's Disease
Parkinson Disease
Active, not recruitingObservational study
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Parkinson Disease
Active, not recruitingPhase 2
A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)
Carcinoma, Non-Small-Cell Lung
RecruitingPhase 3
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Cervical Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Theresa Neumann, PhD study director
Clinical Trials Prothena Biosciences Inc
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing PRX002 in people with Parkinson's Disease, run by Prothena Biosciences Limited at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 10 Feb 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety and tolerability as determined by number of subjects with adverse events (time frame: up to 3 months). The study lists 9 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Feb 2015.